A US retrospective cohort study found no association between angiotensin-converting enzyme inhibitors (ACEI) or angiotensin II receptor blockers (ARB) use and COVID-19 test positivity. The study included 18 472 patients tested for COVID-19 (mean age 49 years, 40% male, and 69% white), 12.4% were taking either ACEIs or ARBs. A positive COVID-19 test result was observed in 9.4% of patients. Among patients who tested positive, 24.3% were admitted to the hospital, 9.3% were admitted to an intensive care unit, and 6.4% required mechanical ventilation. Overlap propensity score weighting showed no significant association of ACEI and/or ARB use with COVID-19 test positivity. These data support various society guidelines to continue current treatment of chronic disease conditions with either ACEI or ARB during the COVID-19 pandemic. Source: https://jamanetwork.com/
A prespecified subgroup analysis of a Chinese randomized clinical trial suggested that salt substitution significantly…
Cognitive Behavioral Therapy (CBT) has been shown to be effective in managing Irritable Bowel Syndrome…
MindShift CBT (Free) – A mobile app based on cognitive-behavioral therapy (CBT) principles, helping users…
A US prospective cohort analysis suggested that supine high blood pressure (BP) regardless of seated…
A UK prospective study on diet and colorectal cancer found a marked positive association for…
A Spanish secondary prevention study suggested that Mediterranean diet might reduce neutrophil levels and slow…
This website uses cookies.